(S)-(+)-4-phenyl-1-(indoline-5-sulfonyl)-4,5-dihydro-2-imidazolone | 203861-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (S)-(+)-4-phenyl-1-(indoline-5-sulfonyl)-4,5-dihydro-2-imidazolone
• 英文别名: (4S)-1-(2,3-dihydro-1H-indol-5-ylsulfonyl)-4-phenylimidazolidin-2-one
• CAS: 203861-19-2
• 化学式: C₁₇H₁₇N₃O₃S
• 分子量: 343.406
• InChiKey: JNSNBCGXHWKDQN-MRXNPFEDSA-N

物化性质

• 密度：
  1.379±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-(+)-4-phenyl-1-(indoline-5-sulfonyl)-4,5-dihydro-2-imidazolone 在 吡啶 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-4-Phenyl-1-[1-(2-phenylamino-acetyl)-2,3-dihydro-1H-indole-5-sulfonyl]-imidazolidin-2-one
  参考文献：
  名称：

  Novel diarylsulfonylurea derivatives as potent antimitotic agents

  摘要：

  A novel series of diarylsulfonylurea derivatives were synthesized and evaluated for interaction with tubulin and for cytotoxicity against human cancer cell lines. These derivatives demonstrated good inhibitory activity against tubulin polymerization, which was well correlated with promising antiproliferative activity as well as G2/M phase cell cycle arrest. Furthermore, several compounds were also efficacious against multidrug-resistant cancer cells, which are resistant to many other known microtubule inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.069
• 作为产物：
  描述：

  (9ci)-2,3-二氢-1-(三氟乙酰基)-1H-吲哚 在 氯磺酸 、 sodium hydroxide 、 氨 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (S)-(+)-4-phenyl-1-(indoline-5-sulfonyl)-4,5-dihydro-2-imidazolone
  参考文献：
  名称：

  Novel diarylsulfonylurea derivatives as potent antimitotic agents

  摘要：

  A novel series of diarylsulfonylurea derivatives were synthesized and evaluated for interaction with tubulin and for cytotoxicity against human cancer cell lines. These derivatives demonstrated good inhibitory activity against tubulin polymerization, which was well correlated with promising antiproliferative activity as well as G2/M phase cell cycle arrest. Furthermore, several compounds were also efficacious against multidrug-resistant cancer cells, which are resistant to many other known microtubule inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.069

文献信息

• Arylsulfonylimidazolone derivatives as an antitumor agent
  申请人：Dong Wha Pharm. Ind. Co., Ltd.

  公开号：US05929103A1

  公开（公告）日：1999-07-27

  The present invention relates to a novel arylsulfonylimidazolone derivative represented by the following formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect: ##STR1## and its pharmaceutically acceptable salt and stereoisomer, in which ----, R.sub.1, and R.sub.2 are as defined in the specification.

  本发明涉及一种新型芳基磺酰基咪唑酮衍生物，其化学式如下(I)，与已知的磺酰脲类抗肿瘤药物相比具有更优异的抗肿瘤活性，且副作用小：##STR1## 以及其药学上可接受的盐和立体异构体，其中----，R.sub.1和R.sub.2在说明书中定义。
• ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT
  申请人：DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD.

  公开号：EP1021437B1

  公开（公告）日：2001-11-14
• US5929103A
  申请人：——

  公开号：US5929103A

  公开（公告）日：1999-07-27
• US5932742A
  申请人：——

  公开号：US5932742A

  公开（公告）日：1999-08-03
• Novel diarylsulfonylurea derivatives as potent antimitotic agents
  作者：Semi Kim、Ji Hyun Park、Sun-Young Koo、Jung In Kim、Min-Hyeung Kim、Ji Eun Kim、Kiwon Jo、Hwan Geun Choi、Sung Bae Lee、Sang-Hun Jung

  DOI：10.1016/j.bmcl.2004.09.069

  日期：2004.12

  A novel series of diarylsulfonylurea derivatives were synthesized and evaluated for interaction with tubulin and for cytotoxicity against human cancer cell lines. These derivatives demonstrated good inhibitory activity against tubulin polymerization, which was well correlated with promising antiproliferative activity as well as G2/M phase cell cycle arrest. Furthermore, several compounds were also efficacious against multidrug-resistant cancer cells, which are resistant to many other known microtubule inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.